Skip to content
PIL Logo

Evorel Sequi

Last Updated on eMC 23-Jun-2016 View document  | Janssen-Cilag Ltd Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23-Jun-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 08-Apr-2015 and displayed until 23-Jun-2016

Reasons for adding or updating:

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 10-Feb-2015 and displayed until 08-Apr-2015

Reasons for adding or updating:

  • Change to section 6 - date of revision

Updated on 30-Apr-2013 and displayed until 10-Feb-2015

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 09-Mar-2012 and displayed until 30-Apr-2013

Reasons for adding or updating:

  • Change to date of revision
  • Change of contra-indications

Updated on 06-Jan-2012 and displayed until 09-Mar-2012

Reasons for adding or updating:

  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to instructions about overdose
  • Change to side-effects

Updated on 03-Jun-2009 and displayed until 06-Jan-2012

Reasons for adding or updating:

  • Change to date of revision
  • Change to drug interactions

Updated on 22-Jan-2009 and displayed until 03-Jun-2009

Reasons for adding or updating:

  • Change to date of revision
  • Change due to user-testing of patient information

Updated on 04-Dec-2008 and displayed until 14-Jan-2009

Reasons for adding or updating:

  • Change to date of revision
  • Change to drug interactions
  • Change to date of revision
  • Change to Marketing Authorisation Holder

Updated on 04-Jun-2008 and displayed until 04-Dec-2008

Reasons for adding or updating:

  • Change to drug interactions

Updated on 03-Nov-2006 and displayed until 04-Jun-2008

Reasons for adding or updating:

  • Change to date of revision

Updated on 30-Oct-2006 and displayed until 03-Nov-2006

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 03-Mar-2006 and displayed until 30-Oct-2006

Reasons for adding or updating:

  • Change of trade or generic name
  • Change to appearance of the medicine
  • Change to, or new, use for medicine
  • Change to storage instructions
  • Change to drug interactions
  • Change of contra-indications
  • Change to warnings or special precautions for use
  • Change to information about driving or using machinery
  • Change to information about pregnancy or lactation
  • Change to side-effects
  • Change to instructions about overdose
  • Change to date of revision

Updated on 05-May-2005 and displayed until 03-Mar-2006

Reasons for adding or updating:

  • Change to Further Information section
  • Change to date of revision

Updated on 06-Apr-2004 and displayed until 05-May-2005

Reasons for adding or updating:

  • Change of manufacturer
  • Change to Further Information section
  • Change to date of revision

Updated on 04-Oct-2001 and displayed until 06-Apr-2004

Reasons for adding or updating:

  • Update to PIL

Updated on 13-Jul-2000 and displayed until 04-Oct-2001

Reasons for adding or updating:

  • No reasons supplied

Company contact details

Janssen-Cilag Ltd

Company image
Address

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG

Fax

+44 (0)1494 567 568

Medical Information e-mail
Medical Information Fax

+44 (0) 1494 567 445

Telephone

+44 (0)1494 567 567

Medical Information Direct Line

+44 (0)800 731 8450

Customer Care direct line

+44 (0)800 731 5550

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

estradiol hemihydrate, norethisterone acetate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue